MedTrace Logo

Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

NCT07552402 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-08-17

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Conditions

  • Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Oral Paclitaxel Solution Plus Fruquintinib

Patients received oral paclitaxel plus fruquintinib in 4-week cycles until disease progression, death, unacceptable toxicity, withdrawal of consent, iscontinuation by the investigator or study completion or termination.

DRUG

Investigator Choice (IC) Chemotherapy

Investigator' choice of chemotherapy is given until disease progression, death, unacceptable toxicity, withdrawal of consent, iscontinuation by the investigator or study completion or termination.

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-10
Primary Completion
2027-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07552402 on ClinicalTrials.gov